Celltrion said Founder and Chairman Seo Jung-jin and Chief Executive Officer Seo Jin-seok will jointly participate in the upcoming 2025 J.P. Morgan Healthcare Conference (JPMHC), the world’s largest pharmaceutical and biotech investment event.

The 43rd annual J.P. Morgan Healthcare Conference will take place from Jan. 13 to 16 in San Francisco, Calif. The event is expected to attract over 550 pharmaceutical and biotech companies and more than 8,000 participants from around the globe.

The presentation is scheduled for 5:15 pm local time on Jan. 14 at the Grand Ballroom of the Westin St. Francis Hotel in San Francisco, the U.S.

During the presentation, Celltrion will disclose a detailed development timeline for its new drug pipeline, followed by an on-site Q&A session with investors.

The presentation will take place on the event’s Main Track. Celltrion stressed that its inclusion on this stage for the second consecutive year highlights its growing influence and reputation as an industry leader.

At the conference, Celltrion will reveal the specific timeline for its 13 innovative drugs – nine ADCs and four multi-specific antibodies – through 2028, including the investigational new drug (IND) filing timeline for each pipeline.

Key updates will include the two ADC-based oncology drugs CT-P70 and CT-P71, previously unveiled at World ADC 2024 conference last year, alongside plans to lead next-generation ADC and multi-specific antibody drug development.

Celltrion has adopted a dual-track approach encompassing both biosimilars and new drug development to enhance its future growth potential.

Leveraging the success of its recently launched novel drug, Zymfentra, in the U.S. market, Celltrion is accelerating efforts in new drug development using advanced modalities.

The company aims to commercialize its first products from this initiative by 2029.

In line with this goal, the company announced at the Celltrion Investor Day in Hong Kong last year that it aims to generate 40 percent of its revenue from innovative drugs by 2030.

"Celltrion plans to share the blueprint for transforming into a global innovative pharmaceutical company at the conference," a Celltrion official said. "Leveraging our expertise and strength as a leading antibody company, we are fully committed to fulfilling the blueprint and establishing ourselves as a global player in novel drug development."